Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Here are ?the details: * Under the deal, Sanofi will obtain global rights to KT501,a tri-specific antibody utilizing Kali Therapeutics' proprietarydiscovery and research platform. * Kali Therapeutics will receive $180 million ?in upfront andnear-term ?payments and is eligible for up to $1.05 billion indevelopment and commercial milestone payments. * If the ?drug is approved, the company will also receivetiered royalties on product sales ranging from the high-singledigits to ?double ?digits. * KT501 is currently ?being tested in an ?early-stage study inrheumatoid arthritis patients to assess its safety and how wellthe drug was tolerated. * Studies in non-human primates showed KT501 stronglyreduced a type of white blood cells called B cell, whilelimiting harmful immune reactions ?that can happen with somesimilar ?treatments, Kali said. * The drug developer, ?which focuses on ?next-generationbiologics, said KT501 is designed to ?target and modulate immunecells that ?trigger autoimmune
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (SNY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]Yahoo! Finance
- Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoire [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoireGlobeNewswire
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website